Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - plegridy
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp065940950f1dbb7c281e0e49d5dfc752
identifier: http://ema.europa.eu/identifier
/EU/1/14/934/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Plegridy 63 micrograms solution for injection in pre-filled syringe
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-065940950f1dbb7c281e0e49d5dfc752
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/14/934/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - plegridy
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
What Plegridy is The active substance in Plegridy is peginterferon beta-1a. Peginterferon beta-1a is a modified long-acting form of interferon. Interferons are natural substances made in the body to help protect from infections and diseases.
What Plegridy is used for This medicine is used to treat relapsing-remitting multiple sclerosis (MS) in adults aged 18 or over.
MS is a long term illness that affects the central nervous system (CNS), including the brain and spinal cord, in which the body s immune system (its natural defences) damages the protective layer (myelin) that surrounds the nerves in the brain and spinal cord. This disrupts the messages between the brain and other parts of the body, causing the symptoms of MS. Patients with relapsing-remitting MS have periods when the disease is not active (remission) in between flare-ups of symptoms (relapses).
Everyone has their own set of MS symptoms. These can include:
How Plegridy works Plegridy seems to work by stopping the body s immune system from damaging your brain and spinal cord. This can help to reduce the number of relapses that you have and slow down the disabling effects of MS. Treatment with Plegridy can help to prevent you from getting worse, although it will not cure MS.
Do not use Plegridy
Warnings and precautions
Talk to your doctor if you have ever had:
Talk to your doctor, pharmacist or nurse before injecting Plegridy if you have any of the conditions listed below. They may get worse while using Plegridy:
Other things to consider when using Plegridy
If you accidentally prick yourself or someone else with the needle in Plegridy, the area affected should be washed immediately with soap and water and a doctor or nurse should be contacted as soon as possible.
Children and adolescents Plegridy is not to be used in children and adolescents below 18 years old. The safety and effectiveness of Plegridy in this age group are not known.
Other medicines and Plegridy Plegridy should be used carefully with medicines that are broken down in the body by a group of proteins called cytochrome P450 (e.g. some medicines used for epilepsy or depression).
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, especially those used to treat epilepsy or depression. This includes any medicines obtained without a prescription.
Sometimes you will need to remind other healthcare professionals that you are being treated with Plegridy. For example, if you are prescribed other medicines, or if you have a blood test. Plegridy may affect the other medicines or the test result.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
No harmful effects on the breastfed newborn/infant are anticipated. Plegridy can be used during breast- feeding.
Driving and using machines
Plegridy has no or negligible influence on the ability to drive and use machines.
Plegridy contains sodium
This medicine contains less than 1 mmol sodium (23 mg), that is to say it is essentially sodium-free .
Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
The usual dose One injection of Plegridy 125 micrograms every 14 days (every two weeks). Try to use Plegridy at the same time on the same day, every time you inject.
Starting Plegridy If you are new to Plegridy, your doctor may advise you to gradually increase your dose so that you can adjust to the effects of Plegridy before taking the full dose. You will be provided with an Initiation Pack containing your first 2 injections: one orange syringe with Plegridy 63 micrograms (for day 0) and one blue syringe with Plegridy 94 micrograms (for day 14).
After that you will be provided with a maintenance pack containing grey syringes with Plegridy 125 micrograms (for day 28 and then every two weeks).
Read the instructions in section 7 Instructions for injecting Plegridy pre-filled syringe at the end of this leaflet before you start using Plegridy. Use the record table printed on the inside of the lid of the Initiation Pack to keep a track of your injection dates.
Injecting yourself Plegridy is to be injected under the skin (subcutaneous injection). Alternate the sites you use for injections. Do not use the same injection site for consecutive injections.
You can inject Plegridy yourself without the help of your doctor, if you have been trained how to do this.
How long to use Plegridy Your doctor will tell you how long you need to keep using Plegridy. It is important to continue using Plegridy regularly. Do not make changes unless your doctor tells you.
If you use more Plegridy than you should You must only inject Plegridy once every 2 weeks.
If you forget to use Plegridy You need to inject Plegridy once every 2 weeks. This regular schedule helps to deliver the treatment as evenly as possible.
If you do miss your usual day, inject as soon as you can and carry on as usual. However, do not inject more than once in a 7-day period. Do not use two injections to make up for a missed injection.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects
Liver problems (common - may affect up to 1 in 10 people) If you get any of these symptoms:
Yellowing of your skin or the whites of your eyes
Itching all over
Feeling sick, being sick (nausea and vomiting)
Easy bruising of the skin
Contact a doctor immediately. They may be signs of a possible liver problem.
Depression (common - may affect up to 1 in 10 people) If you:
Feel unusually sad, anxious or worthless or
Have thoughts about suicide
Contact a doctor immediately.
Serious allergic reaction (uncommon - may affect up to 1 in 100 people) If you get any of these:
Difficulty breathing
Swelling around the face (lips, tongue or throat)
Skin rashes or redness
Contact a doctor immediately.
Seizures (uncommon - may affect up to 1 in 100 people) If you have a seizure or a fit
Contact a doctor immediately.
Injection site damage (rare - may affect up to 1 in 1,000 people) If you get any of these symptoms:
Any break in the skin together with swelling, inflammation or fluid leaking around the injection site
Contact a doctor for advice.
Kidney problems including scarring that may reduce your kidney function
(rare - may affect up to 1 in 1,000 people) If you get some or all of these symptoms:
Foamy urine
Fatigue
Swelling, particularly in the ankles and eyelids, and weight gain.
Contact a doctor as they may be signs of a possible kidney problem.
Blood problems
(rare - may affect up to 1 in 1,000 people) The following may occur: Blood clots in the small blood vessels that can affect your kidneys (thrombotic thrombocytopenic purpura or haemolytic uremic syndrome). Symptoms may include increased bruising, bleeding, fever, extreme weakness, headache, dizziness or light-headedness. Your doctor may find changes in your blood and the function of your kidneys.
If you get some or all of these symptoms:
Other side effects Very common side effects
(may affect more than 1 in 10 people)
Flu-like symptoms Flu-like symptoms are more common when you first start using Plegridy. They gradually get less as you keep using your injections. See below for simple ways to manage these flu-like symptoms if you get them.
Three simple ways to help reduce the impact of flu-like symptoms:
Common side effects (may affect up to 1 in 10 people)
Uncommon side effects (may affect up to 1 in 100 people)
Frequency not known
(frequency cannot be estimated from the available data)
Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
In order to improve the traceability of this medicine, your doctor or pharmacist should record the name and the lot number of the product you have been given in your patient file. You may also wish to make a note of these details in case you are asked for this information in the future.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and the label after EXP . The expiry date refers to the last day of that month.
Store in the original package in order to protect from light. Only open the pack when you need a new syringe.
Store in a refrigerator (fridge) 2 -8 C.
Do not freeze. Throw away any Plegridy that is accidentally frozen.
Plegridy can be kept outside a fridge at room temperature (up to 25 C) for up to 30 days but it must be kept away from light.
Packs can be taken out of the fridge and then put back in a fridge more than once if you need to.
Make sure the time the syringes spend out of a fridge is no more than 30 days in total.
Throw away any syringe that is kept out of the fridge for more than 30 days.
If you are unsure of the number of days you have kept a syringe out of the fridge, throw the syringe away.
Do not use this medicine if you notice any of the following:
If the syringe is broken.
If the solution is coloured, cloudy or you can see particles floating in it.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Plegridy contains
The active ingredient is peginterferon beta-1a.
Each 63 microgram pre-filled syringe contains 63 micrograms of peginterferon beta-1a in 0.5 mL solution for injection. Each 94 microgram pre-filled syringe contains 94 micrograms of peginterferon beta-1a in 0.5 mL solution for injection. Each 125 microgram pre-filled syringe contains 125 micrograms of peginterferon beta-1a in 0.5 mL solution for injection.
The other ingredients are: Sodium acetate trihydrate, acetic acid glacial, arginine hydrochloride, polysorbate 20 and water for injections (see Section 2 Plegridy contains sodium ).
What Plegridy looks like and contents of the pack Plegridy is a clear and colourless solution for injection in a glass pre-filled syringe with an attached needle.
Pack sizes:
Not all pack sizes may be marketed.
Marketing Authorisation Holder Biogen Netherlands B.V. Prins Mauritslaan 1171 LP Badhoevedorp The Netherlands
Manufacturer FUJIFILM Diosynth Biotechnologies Denmark ApS Biotek All 1 DK-3400 Hiller d Denmark
Biogen Netherlands B.V. Prins Mauritslaan 1171 LP Badhoevedorp The Netherlands
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien Biogen Belgium NV/SA +32 2 2191Lietuva Biogen Lithuania UAB +370 5 259 6
+359 2 962 12 Luxembourg/Luxemburg Biogen Belgium NV/SA +32 2 2191 esk republika Biogen (Czech Republic) s.r.o. +420 255 706 Magyarorsz g Biogen Hungary Kft. +36 1 899 9Danmark Biogen Denmark A/S +45 77 41 57 Malta Pharma. MT Ltd.. +356 21337Deutschland Biogen GmbH +49 (0) 89 99 6Nederland Biogen Netherlands B.V. +31 20 542 2Eesti Biogen Estonia O
+372 618 9Norge Biogen Norway AS +47 23 40 01
Genesis Pharma SA +30 210 8771 sterreich Biogen Austria GmbH +43 1 484 46 Espa a Biogen Spain S.L. +34 91 310 7Polska Biogen Poland Sp. z o.o. +48 22 351 51 France Biogen France SAS +33 (0)1 41 37 9Portugal Biogen Portugal
Sociedade Farmac utica, Unipessoal Lda. +351 21 318 8Hrvatska Biogen Pharma d.o.o. +385 1 775 73 Rom nia Johnson & Johnson Romania S.R.L.
+40 21 207 18 Ireland Biogen Idec (Ireland) Ltd. +353 (0)1 463 7Slovenija Biogen Pharma d.o.o. +386 1 511 02 sland Icepharma hf +354 540 8Slovensk republika Biogen Slovakia s.r.o. +421 2 323 34Italia Biogen Italia s.r.l. +39 02 584 9Suomi/Finland Biogen Finland Oy +358 207 401
Genesis Pharma Cyprus Ltd +357 22 76 57 Sverige Biogen Sweden AB +46 8 594 113 Latvija Biogen Latvia SIA +371 68 688 United Kingdom (Northern Ireland) Biogen Idec (Ireland) Limited +44 (0) 1628 50 1This leaflet was last revised in <{MM/YYYY}> <{month YYYY}>.
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-065940950f1dbb7c281e0e49d5dfc752
Resource Composition:
Generated Narrative: Composition composition-en-065940950f1dbb7c281e0e49d5dfc752
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/14/934/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - plegridy
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp065940950f1dbb7c281e0e49d5dfc752
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp065940950f1dbb7c281e0e49d5dfc752
identifier:
http://ema.europa.eu/identifier
/EU/1/14/934/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Plegridy 63 micrograms solution for injection in pre-filled syringe
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en